Literature DB >> 18581835

Genetic factors in drug metabolism.

Donna J Belle1, Harleen Singh.   

Abstract

Patients vary widely in their response to drugs. Having an understanding of the pharmacokinetic and pharmacodynamic properties of various medications is importantwhen assessing ethnic differences in drug response. Genetic factors can account for 20 to 95 percent of patient variability. Genetic polymorphisms for many drug-metabolizing enzymes and drug targets (e.g., receptors) have been identified. Although currently limited to a few pathways, pharmacogenetic testing may enable physicians to understand why patients react differently to various drugs and to make better decisions about therapy. Ultimately, this understanding may shift the medical paradigm to highly individualized therapeutic regimens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18581835

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  19 in total

1.  Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects.

Authors:  Aurel Constant Allabi; Yves Horsmans; Jean-Claude Alvarez; André Bigot; Roger K Verbeeck; Umit Yasar; Jean-Luc Gala
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-08-03       Impact factor: 2.441

2.  Identifying populations sensitive to environmental chemicals by simulating toxicokinetic variability.

Authors:  Caroline L Ring; Robert G Pearce; R Woodrow Setzer; Barbara A Wetmore; John F Wambaugh
Journal:  Environ Int       Date:  2017-06-16       Impact factor: 9.621

Review 3.  When to suspect a genetic syndrome.

Authors:  Benjamin D Solomon; Maximilian Muenke
Journal:  Am Fam Physician       Date:  2012-11-01       Impact factor: 3.292

4.  Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.

Authors:  Farhana Islam; Ilona Gorbovskaya; Daniel J Müller
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Assessment of the clinical utility of pharmacogenetic guidance in a comprehensive medication management service.

Authors:  Idaliz Rodríguez-Escudero; Julio A Cedeño; Ileana Rodríguez-Nazario; Gledys Reynaldo-Fernández; Leyanis Rodríguez-Vera; Niretzy Morales; Braulio Jiménez-Vélez; Gualberto Ruaño; Jorge Duconge
Journal:  J Am Coll Clin Pharm       Date:  2020-05-02

6.  Bringing pharmacomicrobiomics to the clinic through well-designed studies.

Authors:  Heidi E Steiner; Hayley K Patterson; Jason B Giles; Jason H Karnes
Journal:  Clin Transl Sci       Date:  2022-08-09       Impact factor: 4.438

7.  Effects of the TCF7L2 and KCNQ1 common variant on sulfonylurea response in type 2 diabetes mellitus patients: a preliminary pharmacogenetic study.

Authors:  Diba Dianatshoar; Tara Alidaee; Negar Sarhangi; Mahdi Afshari; Hamid Reza Aghaei Meybodi; Mandana Hasanzad
Journal:  J Diabetes Metab Disord       Date:  2022-01-11

8.  Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: with an Application to Treating Type 2 Diabetes Patients with Insulin Therapies.

Authors:  Yuanjia Wang; Haoda Fu; Donglin Zeng
Journal:  J Am Stat Assoc       Date:  2017-03-31       Impact factor: 5.033

9.  African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

Authors:  Alvin F Wells; Patricia A MacDonald; Solomon Chefo; Robert L Jackson
Journal:  BMC Musculoskelet Disord       Date:  2012-02-09       Impact factor: 2.362

10.  Disparities in allele frequencies and population differentiation for 101 disease-associated single nucleotide polymorphisms between Puerto Ricans and non-Hispanic whites.

Authors:  Josiemer Mattei; Laurence D Parnell; Chao-Qiang Lai; Bibiana Garcia-Bailo; Xian Adiconis; Jian Shen; Donna Arnett; Serkalem Demissie; Katherine L Tucker; Jose M Ordovas
Journal:  BMC Genet       Date:  2009-08-14       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.